Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill.

Autor:	Chandrasekar AP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN, United States.; Division of Infectious Diseases, Mayo Clinic, Rochester, MN, United States., Maynes M; Department of Immunology, Mayo Clinic, Rochester, MN, United States.; Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States., Badley AD; Division of Infectious Diseases, Mayo Clinic, Rochester, MN, United States.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Mar 05; Vol. 14, pp. 1354502. Date of Electronic Publication: 2024 Mar 05 (Print Publication: 2024).
DOI:	10.3389/fcimb.2024.1354502
Abstrakt:	HIV cure still remains an elusive target. The "Shock and Kill" strategy which aims to reactivate HIV from latently infected cells and subsequently kill them through virally induced apoptosis or immune mediated clearance, is the subject of widespread investigation. NF-κB is a ubiquitous transcription factor which serves as a point of confluence for a number of intracellular signaling pathways and is also a crucial regulator of HIV transcription. Due to its relatively lower side effect profile and proven role in HIV transcription, the non-canonical NF-κB pathway has emerged as an attractive target for HIV reactivation, as a first step towards eradication. A comprehensive review examining this pathway in the setting of HIV and its potential utility to cure efforts is currently lacking. This review aims to summarize non-canonical NF-κB signaling and the importance of this pathway in HIV shock-and-kill efforts. Competing Interests: AB is supported by grants from NIAID grants AI110173 and AI120698 Amfar #109593 and Mayo Clinic HH Sheikh Khalifa Bin Zayed Al-Nahyan Named Professorship of Infectious Diseases. AB is a paid consultant for Abbvie, Gilead, Freedom Tunnel, Pinetree therapeutics Primmune, Immunome, MarPam, Rion, Symbiosis, NexImmune and Flambeau Diagnostics, is a paid member of the DSMB for Corvus Pharmaceuticals, Equilium, CSL Behring, and Excision Biotherapeutics, has received fees for speaking for Reach MD, Peer Voice, and Medscape, owns equity for scientific advisory work in Tier 1 Bio, Zentalis, Rion, and Nference, and is founder and President of Splissen therapeutics, and Member of the Board of Attivare. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Chandrasekar, Maynes and Badley.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu